Recent developments highlight progress in cancer immunotherapy, including Genmab and AbbVie’s Epkinly demonstrating positive Phase 3 results for follicular lymphoma, potentially enabling earlier treatment lines. New studies also uncover molecular drivers such as Annexin A2 in glioma progression and integrative multi-omics analyses revealing T-cell exhaustion mechanisms in chronic lymphocytic leukemia. Meanwhile, novel nanomaterial-based drug delivery systems and bispecific antibody therapeutics are expanding options for precision oncology.